To the Moon
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Been following this one for a while now, glad to see the stock perk up on positive news. Will be staying tuned for updates on $HZHI
Horizons Holdings International UpdatePress Release | 12/17/2018
Horizons Holdings International, Corp. (HZHI) (the "Company"), a Delaware company, is pleased to announce that it will soon be updating corporate information and structures to reflect the companys activities for the past few years. Management anticipates becoming current in all filings including financials to meet the alternate markets reporting requirements. We are in discussions with auditing firms to allow us to advance to QB status and to become a reporting issuer.
25.395 Million traded so far on COBI, .0004 bid is firm and took some in. Only traded at .0005 for the first 25minutes. Looking good here
Bid building at .0003, shes gearing up for her next leg... $COBI
27 Milly just bought at .0004 $COBI
Followed $COBI for years it would be nice to see something actually happen for real this time. Market closed tomorrow in observance of former President Bush passing. Let's see what Thursday brings!
More significant news from $IVST out this am, should equate to more upside in the stock! PPS Has been holding above the moving averages and the uptrend is extremely strong with this one. Go $IVST
More significant news from $IVST, should equate to more upside in the stock! PPS Has been holding above the moving averages and the uptrend is extremely strong with this one.
In Today's Press Release for $IVST, it was reported Innovest Energy Group has sold five (5) Demand Cost Reduction (DCR) solutions since April, 2018 representing $958,000 in base charges and forecasted billing of $1.1 million for these DCR contracts.
Yesterday, the team closed it’s fifth contract, this one $376,392, confirming the potential growth and recent success of this new solution from the Innovest Energy Group, which is part of the commercial and industrial division.
https://finance.yahoo.com/news/innovest-global-provides-one-million-130000125.html
$IVST fresh news out...
Innovest Global Announces Elite Biotech Team
https://www.otcmarkets.com/stock/IVST/news/Innovest-Global-Announces-Elite-Biotech-Team?id=211800
CLEVELAND, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Innovest Global Inc. (OTC Markets: IVST) (the “Company” or “Innovest”), a conglomerate with operations in commercial and industrial products and services, biotechnology, and construction & building materials, is thrilled to welcome four of the worlds foremost scientific experts in their fields, to its newly formed Biotech development team. Serving under the leadership of Dr. Dwain Morris-Irvin, the Biotech Division President, this world-class Advisory Board was hand selected to assist him in achieving and evaluating deal flow.
The opportunities the Biotechnology Division will be pursuing involve highly complex concepts in a rapidly evolving market with life saving technologies. Dr. Morris-Irvin has been diligently laying the groundwork for the division for months and proudly introduces his colleagues and new Innovest Global team members; Introducing Dr. Laina King, Dr. Andrew Norris, Dr. Malin Parmar, and Dr. Lachlan Thompson (full biographies below).
“Dr. Morris-Irvin is one of the top scientists in the world in his field, and it takes such a person with his success characteristics to lead an effort of this magnitude. I’m so incredibly impressed by his diligence and the focused, long-term value mindset that we all share at Innovest. After a few months with him on the job I would argue that we have quite possibly one of the most qualified, the most connected and certainly one of the most equipped biotech teams in the country. On behalf of the entire Innovest family, we are honored by their contribution and thank and welcome them enthusiastically,” said Dan Martin, Innovest Chairman and Chief Executive Officer.
Biographies:
Dr. Laina King
Dr. Laina King is a management consultant, administrator, researcher, external grant reviewer and tenured professor with more than 15 years of administrative experience in the for-profit, not-for-profit, federal agency and academic environments. She obtained her doctoral and postdoctoral training at the University of Michigan, Harvard and the Coverdale Institute. Her past 5 years have been with the United States Department of Health and Human Services Food & Drug Administration (FDA/CDER & FDA/OEA) and National Institutes of Health Office of the NIH Director. Prior to these engagements, she was a senior administrator and Principal Investigator at Keystone Symposia on Molecular & Cellular Biology, Associate Academic Dean and Professor of Pharmaceutical Sciences in a college of pharmacy and a tenured Professor of Management at an AACSB school of business. Significant academic appointments include being a voting Member of the AMA/AAMC Liaison Committee on Medical Education (LCME), Commissioner at the North Central Association of Colleges & Schools and Steering Committee Member of the CDC Health Disparities Institute Development Group. Her research, national presentations and publications are in the areas of organizational behavior, advanced academic mentoring & positioning, graduate education training program implementation and operational management. She has authored numerous peer reviewed articles and book chapters and has edited a three volume book series on managed care. Her consulting experience includes work with the Military District of Washington, Japan Consultant for the Department of Defense, American Council on Education and multiple health care professional credentialing agencies.
Dr. Andrew Norris
Dr. Andrew Norris has a varied background in both business and the technology sector. He is Co-founder of The Midvale Group LLC in 2002, consulting in both the technology and biotechnology sector. Dr. Norris has also Co-founded BCN Biosciences in Pasadena CA (2005), which is a privately held biotechnology company whose principal focus is in the area of oncology drug development. Dr. Norris has been directly responsible for, or co-raised over $20M in funding for the technology and Biotechnology sector. He currently serves as an officer/director at BCN Biosciences and also holds a research faculty position at the University of California Los Angeles Department of Neuropsychiatry. Dr. Norris received his PhD from UCLA School of Medicine, Department of Molecular & Medical Pharmacology and Chemistry. His research focused on synthesizing molecular inhibitors against cancer cells. He also trained in the Surgical Oncology Department at UCLA focusing his research on novel drug discovery for breast cancer patients.
Dr. Malin Parmar
Dr. Malin Parmar is a Professor in cellular neuroscience at Lund University. Together with her lab she has shown in a series of high profile publications how human fibroblasts can be converted into neurons, how glial cells can be reprogrammed into neurons in vivo, and how functional dopamine neurons can be generated from human embryonic stem cells. She is the recipient of an ERC starting grant and an ERC Consolidator grant and was recently awarded a New York Stem Cell Foundation – Robertson investigator. Her research has a strong translational focus and she collaborates within European and International networks as well as Industry partners to develop new, cell-based therapies for Brain Repair with focus on Parkinson’s Disease.
Dr. Lachlan Thompson
Dr. Lachlan Thompson, Associate Professor is a Principal Research Fellow at the Florey Institute for Neuroscience and Mental Health. He heads a research program dedicated to regenerative approaches to repair of the central nervous system, with a special focus on the use of pluripotent stem cells for functional reconstruction of circuitry affected in Parkinson’s disease, stroke and motor neuron disease. He has contributed more than 50 research papers on this topic in leading journals including the Journal of Neuroscience, Neurobiology of Disease, Proceedings of the National Academy of Science, Brain and Cell Reports. Dr. Thompson is a partner investigator in the Australian government’s major Stem Cells initiative where he sits on the committee for clinical translation and commercialisation and plays an active role in contributing to policy making on the regulation of experimental stem cell therapies. He also sits on the board of the Network for European CNS Transplantation and Repair and is president of the Asia-Pacific Association for Neural Transplantation and Repair. Dr Thompson brings a wealth of experience in cutting-edge technology driving pre-clinical research in regenerative approaches to brain repair and also in understanding of the regulatory frameworks governing clinical translation and commercialisation of stem cell therapies.
About Innovest Global, Inc.
Innovest Global, Inc. (OTC Markets: IVST) is a conglomerate with operations in three divisions, which include commercial and industrial products and services, energy, biotechnology, health sciences, construction, and building materials. The primary growth strategy of Innovest Global Inc is to acquire existing companies in a select few industries and attract new customers in cost effective ways. Currently, Innovest Global Inc has a Commercial & Industrial Division, a Biotechnology & Health Services Division, and a Construction & Building Materials Division.
For more information, please visit: http://www.innovestglobal.com, and follow us on Twitter and Facebook @innovestglobal.
$IVST In the News, Innovest Global Announces Elite Biotech Team
https://www.otcmarkets.com/stock/IVST/news/Innovest-Global-Announces-Elite-Biotech-Team?id=211800
CLEVELAND, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Innovest Global Inc. (OTC Markets: IVST) (the “Company” or “Innovest”), a conglomerate with operations in commercial and industrial products and services, biotechnology, and construction & building materials, is thrilled to welcome four of the worlds foremost scientific experts in their fields, to its newly formed Biotech development team. Serving under the leadership of Dr. Dwain Morris-Irvin, the Biotech Division President, this world-class Advisory Board was hand selected to assist him in achieving and evaluating deal flow.
The opportunities the Biotechnology Division will be pursuing involve highly complex concepts in a rapidly evolving market with life saving technologies. Dr. Morris-Irvin has been diligently laying the groundwork for the division for months and proudly introduces his colleagues and new Innovest Global team members; Introducing Dr. Laina King, Dr. Andrew Norris, Dr. Malin Parmar, and Dr. Lachlan Thompson (full biographies below).
“Dr. Morris-Irvin is one of the top scientists in the world in his field, and it takes such a person with his success characteristics to lead an effort of this magnitude. I’m so incredibly impressed by his diligence and the focused, long-term value mindset that we all share at Innovest. After a few months with him on the job I would argue that we have quite possibly one of the most qualified, the most connected and certainly one of the most equipped biotech teams in the country. On behalf of the entire Innovest family, we are honored by their contribution and thank and welcome them enthusiastically,” said Dan Martin, Innovest Chairman and Chief Executive Officer.
Biographies:
Dr. Laina King
Dr. Laina King is a management consultant, administrator, researcher, external grant reviewer and tenured professor with more than 15 years of administrative experience in the for-profit, not-for-profit, federal agency and academic environments. She obtained her doctoral and postdoctoral training at the University of Michigan, Harvard and the Coverdale Institute. Her past 5 years have been with the United States Department of Health and Human Services Food & Drug Administration (FDA/CDER & FDA/OEA) and National Institutes of Health Office of the NIH Director. Prior to these engagements, she was a senior administrator and Principal Investigator at Keystone Symposia on Molecular & Cellular Biology, Associate Academic Dean and Professor of Pharmaceutical Sciences in a college of pharmacy and a tenured Professor of Management at an AACSB school of business. Significant academic appointments include being a voting Member of the AMA/AAMC Liaison Committee on Medical Education (LCME), Commissioner at the North Central Association of Colleges & Schools and Steering Committee Member of the CDC Health Disparities Institute Development Group. Her research, national presentations and publications are in the areas of organizational behavior, advanced academic mentoring & positioning, graduate education training program implementation and operational management. She has authored numerous peer reviewed articles and book chapters and has edited a three volume book series on managed care. Her consulting experience includes work with the Military District of Washington, Japan Consultant for the Department of Defense, American Council on Education and multiple health care professional credentialing agencies.
Dr. Andrew Norris
Dr. Andrew Norris has a varied background in both business and the technology sector. He is Co-founder of The Midvale Group LLC in 2002, consulting in both the technology and biotechnology sector. Dr. Norris has also Co-founded BCN Biosciences in Pasadena CA (2005), which is a privately held biotechnology company whose principal focus is in the area of oncology drug development. Dr. Norris has been directly responsible for, or co-raised over $20M in funding for the technology and Biotechnology sector. He currently serves as an officer/director at BCN Biosciences and also holds a research faculty position at the University of California Los Angeles Department of Neuropsychiatry. Dr. Norris received his PhD from UCLA School of Medicine, Department of Molecular & Medical Pharmacology and Chemistry. His research focused on synthesizing molecular inhibitors against cancer cells. He also trained in the Surgical Oncology Department at UCLA focusing his research on novel drug discovery for breast cancer patients.
Dr. Malin Parmar
Dr. Malin Parmar is a Professor in cellular neuroscience at Lund University. Together with her lab she has shown in a series of high profile publications how human fibroblasts can be converted into neurons, how glial cells can be reprogrammed into neurons in vivo, and how functional dopamine neurons can be generated from human embryonic stem cells. She is the recipient of an ERC starting grant and an ERC Consolidator grant and was recently awarded a New York Stem Cell Foundation – Robertson investigator. Her research has a strong translational focus and she collaborates within European and International networks as well as Industry partners to develop new, cell-based therapies for Brain Repair with focus on Parkinson’s Disease.
Dr. Lachlan Thompson
Dr. Lachlan Thompson, Associate Professor is a Principal Research Fellow at the Florey Institute for Neuroscience and Mental Health. He heads a research program dedicated to regenerative approaches to repair of the central nervous system, with a special focus on the use of pluripotent stem cells for functional reconstruction of circuitry affected in Parkinson’s disease, stroke and motor neuron disease. He has contributed more than 50 research papers on this topic in leading journals including the Journal of Neuroscience, Neurobiology of Disease, Proceedings of the National Academy of Science, Brain and Cell Reports. Dr. Thompson is a partner investigator in the Australian government’s major Stem Cells initiative where he sits on the committee for clinical translation and commercialisation and plays an active role in contributing to policy making on the regulation of experimental stem cell therapies. He also sits on the board of the Network for European CNS Transplantation and Repair and is president of the Asia-Pacific Association for Neural Transplantation and Repair. Dr Thompson brings a wealth of experience in cutting-edge technology driving pre-clinical research in regenerative approaches to brain repair and also in understanding of the regulatory frameworks governing clinical translation and commercialisation of stem cell therapies.
About Innovest Global, Inc.
Innovest Global, Inc. (OTC Markets: IVST) is a conglomerate with operations in three divisions, which include commercial and industrial products and services, energy, biotechnology, health sciences, construction, and building materials. The primary growth strategy of Innovest Global Inc is to acquire existing companies in a select few industries and attract new customers in cost effective ways. Currently, Innovest Global Inc has a Commercial & Industrial Division, a Biotechnology & Health Services Division, and a Construction & Building Materials Division.
For more information, please visit: http://www.innovestglobal.com, and follow us on Twitter and Facebook @innovestglobal.
$IVST is up 1640% YTD from $0.023 on zero revenue to 0.40 on $34 million revenue.
$IVST is up 1640% YTD from $0.023 on zero revenue to 0.40 on $34 million revenue.
$IVST Video Chart, a thing of beauty!!!
https://ih.advfn.com/videos/stock-chart/innovest-global-inc-otcmkts-ivst-video-chart-for-11-28-18_nVn_OU4atnE
$IVST Video Chart, a thing of beauty!!!
https://ih.advfn.com/videos/stock-chart/innovest-global-inc-otcmkts-ivst-video-chart-for-11-28-18_nVn_OU4atnE
$IVST Video Chart, a thing of beauty!!!
https://ih.advfn.com/videos/stock-chart/innovest-global-inc-otcmkts-ivst-video-chart-for-11-28-18_nVn_OU4atnE
$PYTG $1.40s back up, Pot/CBD stocks took off yesterday when Jeff Sessions stepped down. I see this going back to $2.00 easily!
Solid news from $PYTG, should see another nice bounce in the PPS https://finance.yahoo.com/news/pyramidion-technology-group-inc-otc-123000053.html
I am with you brotha, these dips for $PYTG will be few and far between in the days and weeks ahead.
$PYTG $1.40 back up on under 10k shares traded. This baby moves on air, once real volume starts to come back in we should be back over $2.00 in a jiffy!
$CBDY News Target Group Inc. Wholly Owned Subsidiary Canary Rx Inc. Provides an Update on Construction at 44,000 Square Foot Norfolk County Cannabis Cultivation Facility
https://www.otcmarkets.com/stock/CBDY/news/Target-Group-Inc-Wholly-Owned-Subsidiary-Canary-Rx-Inc-Provides-an-Update-on-Construction-at-44000-Square-Foot-Norfolk-C?id=208583
NORFOLK COUNTY, ON, Oct. 30, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Target Group Inc. (OTCQB: CBDY) today announced that its wholly owned subsidiary, Canary Rx Inc. ("Canary") (the “Company”) is pleased to provide an update on construction progress at the Company’s 44,000 square foot Norfolk County cannabis cultivation facility.
Canary began leasing the Norfolk County site in July of 2014, and with support from local authorities, construction was initiated in September of 2017. Since then, extensive demolition and structural upgrades have been carried out at the site.
Construction remains on schedule for completion in mid-January 2019. Our crews have made significant progress over the summer, plus the city has finished upgrading the utilities and infrastructure surrounding the facility. Freezer panels are being installed on the interior walls, the ceiling will follow shortly, at which point the individual rooms can be completed. The building is being equipped with customized HVAC, plumbing, and electrical services in layers to ensure a deliberate and seamless finish. Installation of the security systems is underway and fencing around the facility is complete. Fitting out of the electrical room is in the final stages, plus the offices and public areas of the facility are nearing completion.
Once complete, the facility will contain eight separate flower rooms, equipped with 1,700 lights. Layout has been engineered to enable a strictly controlled and optimized environment, and weekly cannabis harvesting. The flower rooms are initially expected to produce 3,600kg of cannabis per year. The facility will also include areas for quality testing, extraction, breeding, processing and packaging of premium cannabis products.
“Canary has come a long way since we first submitted our application in June 2015. Progress at the facility is increasingly exciting to watch as construction nears completion. We look forward to planting our first crops, and then providing a premium cannabis experience to Canadian consumers,” said Randall MacLeod, President and CEO of Canary.
About Canary RX Inc.
Canary Rx Inc. (“Canary”) is a final-stage Licensed Producer (“LP”) applicant, in active review with Health Canada. Situated in Ontario’s Garden, Norfolk County, Canary lies nestled amongst the shores of Lake Erie in a vibrant, agricultural community. The Company’s 44,000 sq. ft. facility is engineered to meet strict quality control standards and will be equipped with the latest environmental control technology. Once complete, it’s expected to produce 3,600kg of cannabis per year. Canary is currently positioning itself as a premium cannabis lifestyle brand, with a focus on producing pure, curated, cannabis products. Our modern, minimalist branding will grow with the company, and evolving social and political conditions, situating us to appeal to both medical and recreational consumers.
About Target Group Inc. (OTCQB: CBDY)
Target Group, Inc. is a diversified and vertically integrated progressive company with focus on both national and international presence. The Company operates a wholly-owned late stage Canadian licensed producer regulated under Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR): Canary RX, which operates a 44,000 square foot facility located in Norfolk County, Ontario. The Company has begun structuring multiple international production and distribution platforms and intends to continue rapidly expanding its global footprint as it focuses on building an iconic brand portfolio whose focus aims at developing cutting edge Intellectual Property among the medical and recreational cannabis markets. Target Group is committed to building industry-leading companies that transform the perception of cannabis and responsibly elevate the overall consumer experience. www.targetgroupinc.ca
$CBDY .21 Close at HOD, looking for a gap up tomorrow and a higher PPS!!!
.21's falling on $CBDY
$CBDY .20 broke L2 resistance shows 40k at .21 and 100k at .30 those are are next hurdles to get over!
PYTG back in the green, last traded at 1.20 +32% hit a high of 1.37 low of day was .97! I love the way this stock trades...
Consolidation is over .17x .20 now. Someone just came in and picked up 33k at .17 to uptick it. Once .20 resistance breaks $CBDY should be smooth sailing!
Looks like $CBDY needed to consolidate a little more before its ready to see its next leg up. Would love to see it get over that resistance at .20. I noticed MAXM show up on the bid which is a great sign. To me that says institutional buyers are trying to accumulate on the bid considering MAXM is a non retail market maker.
Every pullback has been followed with impressive bounces, $PYTG great trading stock!
I think today is the day $CBDY cracks into .20s and doesn't look back! Next stop .50 then $1.00 IMO
*Wisp not Whisp
$CBDY news is huge, think of the Whisp as the Kuerig to Cannabis. $CBDY can go direct to consumer with product from their 40k square foot grow operation to their own vaporizer https://globenewswire.com/news-release/2018/10/24/1626449/0/en/First-Cannabis-Company-to-Bring-Innovative-Pod-based-Vaporizing-Technology-to-Canada-Europe.html
Solid News from $PYTG this morning, nice to see the company following through on its acquisition strategy! https://www.otcmarkets.com/stock/PYTG/news/Pyramidion-Technology-Group-Inc-PYTG-Announces-Closing-Its-Acquisition-With-Established-CBD-Company-NxGen-Brands-LLC?id=207986
$PYTG Nice snag down here, been eyeing this for a while. Was recently over $2.00 these prices down here are perfect to snatch up for a bounce. Level 2 is thin to $1.70
Is it Monday yet? Excited to see what this week brings for $CBDY. Higher highs and higher lows mean the Bulls remain in total control!
That is great news, $CBDY SS is even tighter than we thought. I was traveling the past couple days, nice to return to an increase in PPS for $CBDY. The other great thing about this play is that its still way under the radar. Hardly anyone is posting here or on other social media channels, once peeps catch on and new eyeballs show up we should head much higher.
Agreed, I think we are in the right place at the right time! $CBDY is flying way under the radar, once it starts getting some new eyes and the proper attention it deserves these prices will be laughable!
LOL No worries, imitation is the highest form of flattery!
Nice copy and paste, that post looks very familiar! $CBDY